[1]陈 荣,谢海道,符秀曼,等.资生丸颗粒联合穴位贴敷治疗慢性肺心病肺气亏虚证疗效研究[J].陕西中医,2022,(12):1793-1796.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.036]
　CHEN Rong,XIE Haidao,FU Xiuman,et al.Effect study on Zisheng Wan combined with acupoint application in treatment of chronic pulmonary heart disease of Feiqi Kuixu type[J].,2022,(12):1793-1796.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.036]
点击复制

资生丸颗粒联合穴位贴敷治疗慢性肺心病肺气亏虚证疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年12期
页码:
1793-1796
栏目:
针灸经络
出版日期:
2022-12-20

文章信息/Info

Title:
Effect study on Zisheng Wan combined with acupoint application in treatment of chronic pulmonary heart disease of Feiqi Kuixu type
作者:
陈 荣; 谢海道; 符秀曼; 朱德天
(海口市中医医院,海南 海口570216)
Author(s):
CHEN Rong; XIE Haidao; FU Xiuman; ZHU Detian
(Haikou Hospital of Traditional Chinese Medicine,Haikou 570216,China)
关键词:
慢性肺心病;  肺气亏虚证;  资生丸颗粒;  穴位贴敷;  炎症因子;  血管内皮功能;  肺动脉压;  生活质量
Keywords:
Chronic pulmonary heart disease;  Feiqi Kuixu type;  Zisheng Wan;  Acupoint application;  Inflammatory factor;  Vascular endothelial function;  Pulmonary artery pressure;  Quality of life
分类号:
R 541.5
DOI:
DOI:10.3969/j.issn.1000-7369.2022.12.036
文献标志码:
A
摘要:
目的:探讨资生丸颗粒联合穴位贴敷在慢性肺心病肺气亏虚证治疗中的应用价值。方法:将慢性肺心病肺气亏虚证患者随机分组,对照组57例患者采用西医常规治疗,观察组57例在对照组基础上联合资生丸颗粒、穴位贴敷治疗,治疗4周后比较两组疗效。结果:治疗后观察组血清血管紧张素Ⅱ(AngⅡ)、转化生长因子-β1(TGF-β1)、内皮素-1(ET-1)、肿瘤坏死因子-α(TNF-α)等水平均低于对照组,一氧化氮(NO)高于对照组,差异有统计学意义(均P<0.05)。治疗后观察组血清总抗氧化能力(T-AOC)、超氧化物歧化酶(SOD)高于对照组,肺动脉平均压(MPAP)低于对照组,差异有统计学意义(均P<0.05)。治疗后观察组1秒率(FEV1/FVC)、心指数(CI)、6 min步行距离(6MWD)高于对照组,明尼苏达心力衰竭生活质量量表(MLHFQ)评分、中医总症状积分低于对照组,差异有统计学意义(均P<0.05)。治疗后观察组总有效率94.74%,高于对照组的80.70%,差异有统计学意义(P<0.05)。结论:慢性肺心病肺气亏虚证患者给予西药联合资生丸颗粒、穴位贴敷治疗,能减轻炎症反应,调节血管内皮功能,促进心肺功能恢复,提高临床疗效。
Abstract:
Objective:To explore application value of Zisheng Wan combined with acupoint application in the treatment of chronic pulmonary heart disease of Feiqi Kuixu type.Methods:All patients with chronic pulmonary heart disease of Feiqi Kuixu type were randomly divided into two groups.57 patients in the control group were treated with routine western medicine,and 57 patients in the observation group on the control group basis treated with Zisheng Wan and acupoint application.The curative effects were compared after 4 weeks of treatment.Results:After treatment,serum angiotensin Ⅱ(Ang Ⅱ),transforming growth factor-β1(TGF-β1),endothelin-1(ET-1)and tumor necrosis factor-α(TNF-α)in the observation group were lower than those in the control group,while serum nitric oxide(NO)was higher,statistically significant differences(all P<0.05).After treatment,serum total antioxidant capacity(T-AOC)and superoxide dismutase(SOD)were higher while the mean pulmonary artery pressure(MPAP)was lower in the observation group,statistically significant differences(all P<0.05).After treatment compared with the control group,the ratio of forced expiratory volume in 1 second/forced vital capacity(FEV1/FVC),cardiac index(CI)and 6 min walking distance(6MWD)in the observation group were higher,while MLHFQ score and total TCM syndrome score were lower in the observation group,statistically significant differences(all P<0.05).The overall effective rate in the observation group was 94.74% higher than that in the control group 80.70% statistically significant differences(P<0.05).Conclusion:Patients with chronic pulmonary heart disease of Feiqi Kuixu type treat with western medicine combined with Zisheng Wan acupoint application can reduce inflammatory response,regulate vascular endothelial function,promote cardiopulmonary function recovery,and improve clinical efficacy.

参考文献/References:

[1] 程燕雯.疏血通注射液治疗慢性阻塞性肺疾病并发肺动脉高压、肺心病的临床研究[J].陕西中医,2016,37(6):657-659.
[2] 崔伟娜.丹参冻干粉联合地尔硫卓治疗肺心病肺动脉高压疗效观察[J].陕西中医,2011,32(8):948-949.
[3] 温一琪,赵 建,苏 和.加味小陷胸汤治疗肺心病右心衰竭的机理探析[J].黑龙江中医药,2021,50(2):158-159.
[4] 宋彦伟,杨如意.中医药治疗慢性肺心病的研究进展[J].中西医结合心血管病电子杂志,2017,5(16):177-178.
[5] 张婉莉,杨 桐,唐 泓,等.不同中医证型慢性肺源性心脏病患者心功能情况的比较研究[J].云南中医中药杂志,2021,42(9):46-48.
[6] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性肺源性心脏病基层诊疗指南[J].中华全科医师杂志,2018,17(12):959-965.
[7] 国家中医药管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:243.
[8] 王贤良,刘洪伟,毛静远,等.基于中国文化改良明尼苏达心力衰竭生存质量量表的测评[J].中国中西医结合杂志,2016,36(9):1072-1075.
[9] 庞海江.通脉逐瘀方联合阿司匹林治疗肺心病急性加重期合并全身炎症反应综合征疗效及对患者血浆D-二聚体、IL-6、BNP的影响[J].陕西中医,2018,39(7):873-875.
[10] 王 艳,周 萍.金匮肾气丸合苓桂术甘汤加味治疗肺心病伴右心衰竭临床研究[J].陕西中医,2017,38(5):581-582.
[11] 王艾青,郭锦丽,牛增志,等.养心汤加减辨治对肺心病缓解期心肺气虚证疾病的进展[J].中国实验方剂学杂志,2020,26(12):139-144.
[12] 徐香梅,徐文华,杨文娜.基于分子对接和系统药理学探讨苓甘五味姜辛汤治疗肺心病的作用机制[J].辽宁中医杂志,2021,48(8):175-177.
[13] 单洁龄.宣肺祛瘀通络法对肺心病肺动脉高压患者血管内生长因子、内皮素和氧化应激水平的影响[J].中国中医急症,2018,27(6):1036-1038.
[14] 万国仕,胡 蔚,马 强,等.舒血宁注射液对慢性肺心病并肺动脉高压患者氧化应激状态的影响[J].浙江中西医结合杂志,2017,27(3):203-206.
[15] 吴 俣,刘良丽,朱晓龙.TGF-β1/Smad通路在养肺保元汤治疗慢性阻塞性肺病合并肺间质纤维化中的作用[J].海南医学,2021,32(2):137-140.
[16] 王 新,王 静.百令胶囊辅助治疗对稳定期COPD患者气道功能及血清气道重塑分子的影响[J].中国现代医学杂志,2019,29(6):88-91.
[17] 阮欢荣,马锦地,李建生,等.慢性肺源性心脏病中医病因病机分析[J].中医学报,2018,33(1):37-41.
[18] 于化江,刘立敏,于 赢,等.补脾益肺汤联合丹参川芎嗪注射液治疗慢性肺源性心脏病的临床疗效及安全性评价[J].河北中医,2016,38(8):1151-1154.
[19] 宋彦伟,杨如意.中医药治疗慢性肺心病的研究进展[J].中西医结合心血管病电子杂志,2017,5(16):177-178.
[20] 黄 凯.益气补肾化痰祛瘀法对缓解期慢性阻塞性肺疾病合并肺心病的疗效[J].世界临床医学,2016,10(17):168-169.

相似文献/References:

[1]王 伟,足巴措,张 旭.补肺汤治疗慢性阻塞性肺疾病急性加重期疗效及对患者Th1/Th2漂移的影响[J].陕西中医,2023,(8):1078.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.018]
　WANG Wei,ZU Bacuo,ZHANG Xu.Effect of Bufei decoction on acute exacerbation of chronic obstructive pulmonary disease and its influence on Th1/Th2 drift[J].,2023,(12):1078.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.018]

备注/Memo

备注/Memo:
基金项目:海南省卫生健康行业科研项目(20A200211)
更新日期/Last Update: 2022-12-09